$4.84
0.41%
Nasdaq, Thu, Aug 14 2025
ISIN
US72940R1023
Symbol
PSTI

Pluristem Therapeutics Inc. Stock price

$4.84
-0.24 4.72% 1M
+0.22 4.76% 6M
+0.57 13.22% YTD
-0.67 12.16% 1Y
-3.40 41.26% 3Y
-64.92 93.06% 5Y
-170.36 97.24% 10Y
+4.66 2,588.89% 20Y
Nasdaq, Closing price Thu, Aug 14 2025
-0.02 0.41%
ISIN
US72940R1023
Symbol
PSTI
Industry

Key metrics

Basic
Market capitalization
$37.9m
Enterprise Value
$36.6m
Net debt
positive
Cash
$26.3m
Shares outstanding
7.8m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
36.8 | 20.3
EV/Sales
35.5 | 19.6
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
0.2%
Return on Equity
-21,758.3%
ROCE
-68.1%
ROIC
-
Debt/Equity
-5.6
Financials (TTM | estimate)
Revenue
$1.0m | $1.9m
EBITDA
$-21.3m | -
EBIT
$-21.6m | $-25.2m
Net Income
$-20.7m | $-24.4m
Free Cash Flow
$-18.2m
Growth (TTM | estimate)
Revenue
202.9% | 465.5%
EBITDA
4.8% | -
EBIT
4.8% | -13.7%
Net Income
4.9% | -16.8%
Free Cash Flow
-7.1%
Margin (TTM | estimate)
Gross
52.1%
EBITDA
-2,062.2% | -
EBIT
-2,087.9%
Net
-2,003.3% | -1,307.7%
Free Cash Flow
-1,761.6%
More
EPS
$-3.2
FCF per Share
$-2.3
Short interest
1.3%
Employees
112
Rev per Employee
$0.0
Show more

Is Pluristem Therapeutics Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,016 stocks worldwide.

Pluristem Therapeutics Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Pluristem Therapeutics Inc. forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Pluristem Therapeutics Inc. forecast:

Buy
86%
Hold
14%

Financial data from Pluristem Therapeutics Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
1.03 1.03
203% 203%
100%
- Direct Costs 0.50 0.50
-
49%
0.54 0.54
-
52%
- Selling and Administrative Expenses 9.88 9.88
5% 5%
959%
- Research and Development Expense 14 14
84% 84%
1,312%
-21 -21
5% 5%
-2,070%
- Depreciation and Amortization 0.27 0.27
0% 0%
26%
EBIT (Operating Income) EBIT -22 -22
5% 5%
-2,096%
Net Profit -21 -21
5% 5%
-2,011%

In millions USD.

Don't miss a Thing! We will send you all news about Pluristem Therapeutics Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Pluristem Therapeutics, Inc. engages in cell therapy development. It develops placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. It focuses on the development, clinical trials and manufacturing of cell therapeutics and related technologies. Its products include Clinical Pipeline, PLX-Immune, PLX-PAD, and PLX-R18. The company was founded by Doron Shorrer on May 11, 2001 and is headquartered in Haifa, Israel.

Head office United States
CEO Yaky Yanay
Employees 112
Founded 2001
Website pluri-biotech.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today